Myriad Genetics Inc (MYGN) 31.48 $MYGN Myriad to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Myriad Genetics Inc (MYGN) 31.48 $MYGN

Myriad to Announce Fiscal Fourth-Quarter 2016 Financial Results on August 9
GlobeNewswire - Tue Jul 26, 3:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 9, 2016. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad's financial performance for the fiscal fourth-quarter and provide a business update.
MYGN: 31.48 (+0.50)

Myriad Announces Positive Results for an EndoPredict(R) Clinical Study Published in the Journal of the National Cancer Institute
Globe Newswire - Mon Jul 11, 10:46AM CDT
"EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX(R)) Across the 10-Year Follow-up Period" in a Large Head-to-Head Breast Cancer Study
MYGN: 31.48 (+0.50)

Look for Shares of Myriad Genetics to Potentially Pullback after Yesterday's 1.63% Rise
Comtex SmarTrend(R) - Wed Jun 22, 2:33PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $30.55 to a high of $32.00. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $31.60 on volume of 597,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 31.48 (+0.50)

Global DNA Repair Drugs Report: Focus on PARP Inhibitors 2016-2026 - Myriad Genetics and Foundation Medicine Have Emerged as the Major Diagnostic Developers - Research and Markets
PR Newswire Europe - Wed Jun 22, 7:11AM CDT
DUBLIN, June 22, 2016 /PRNewswire/ --
MYGN: 31.48 (+0.50)

Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 31.48 (+0.50), BAH: 30.76 (-0.12), INCR: 42.76 (-1.75), QGEN: 26.80 (unch)

Crescendo Bioscience Announces that New Data on Vectra(R) DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress
GlobeNewswire - Fri Jun 10, 6:05AM CDT
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA test to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at European League Against Rheumatism (EULAR) meeting being held June 8-11, 2016, in London. Vectra DA test is the first and only multi-biomarker blood test validated to measure disease activity in patients with RA and has been evaluated in multiple studies, resulting in 23 scientific peer-reviewed publications.
MYGN: 31.48 (+0.50)

Myriad Board Approves $200 Million Increase in Share Repurchase Program
GlobeNewswire - Tue Jun 07, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Company had repurchased greater than $1.1 billion of stock since the inception of the program in 2010 at an average share price of $26.16.
MYGN: 31.48 (+0.50)

Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:00 a.m. Pacific on June 8, 2016, at the Terranea Resort in Rancho Palos Verdes, California.
MYGN: 31.48 (+0.50)

Myriad myRisk(R) Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk Hereditary Cancer test will be featured in oral presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the importance of using a 25-gene panel to evaluate risk for hereditary breast and ovarian cancers.
MYGN: 31.48 (+0.50)

Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk Hereditary Cancer test will be featured in podium presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the expanding benefits of gene panel testing and underscore the need for gene panel testing to become the standard-of-care for hereditary cancer risk evaluation.
MYGN: 31.48 (+0.50)

Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 24.43 (+0.15), SRDX: 27.06 (-0.37), MYGN: 31.48 (+0.50), BAX: 48.50 (+0.48)

After Yesterday's Rally of 1.25% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:53PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $34.27 to a high of $34.78. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.49 on volume of 779,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 31.48 (+0.50)

Myriad Acquires Sividon Diagnostics
Globe Newswire - Tue May 31, 3:05PM CDT
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict(R)
MYGN: 31.48 (+0.50)

Watch for Myriad Genetics to Potentially Rebound After Falling 2.83% Yesterday
Comtex SmarTrend(R) - Thu May 26, 3:24PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 31.48 (+0.50)

After Yesterday's Decline of 2.83%, Myriad Genetics Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 26, 3:22PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 31.48 (+0.50)

Myriad Genetics' Statement on HIPAA Complaint from Four Patients
GlobeNewswire - Thu May 19, 3:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. The Company believes it has complied with these requests and provided these four patients with their designated record set and all requested personal health information. Therefore, we believe the complaint lacks merit and should not be accepted.
MYGN: 31.48 (+0.50)

Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information
GlobeNewswire - Wed May 18, 4:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.
MYGN: 31.48 (+0.50)

Myriad to Present New Research at the 2016 ASCO Annual Meeting
GlobeNewswire - Wed May 18, 4:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill. Key podium presentations will highlight the safety and validity of the Myriad myRisk Hereditary Cancer multigene panel test in assessing hereditary cancer risk. Abstracts of the Company's presentations are available at: abstracts.asco.org.
MYGN: 31.48 (+0.50)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 52

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 182

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 149

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 202

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 111

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 163

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 64

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 0

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
BD&J's Workplace Recognition Meets Los Angeles Growth Test

Updated Category News Views 58

A workplace award is not a verdict from a jury, but it can still tell you where a law firm is putting its money and attention. BD&J Injury Lawyers landed on the Los Angeles Business Journal's 2026 list of most admired law firms to work for, announced November 18. For a personal-injury practice trying to deepen its footing in a brutally crowded Los Angeles market, that is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading

Top 5 Most Recently Viewed Articles

Delta Air Lines and Taiwan Semiconductor: Earnings Insights

Updated Category News Views 120

Delta Air Lines: Anticipated Earnings Report As we look ahead to the earnings season, all eyes are on Delta Air Lines. Sales projections indicate a modest increase of 0.8%, yet analysts predict a significant downturn of 15.2% in earnings. Despite some downward adjustments from analysts, Delta boasts an impressive history of surprising on earnings. Delta operates multiple...

Continue Reading
Vera Bradley Sees Share Price Decline Amid Revenue Challenges

Updated Category News Views 153

Vera Bradley Experiences Revenue Challenges Amid Market Pressures Vera Bradley, Inc. (NASDAQ: VRA) has recently faced a noteworthy drop in its stock price, which sank by 12.65% in premarket trading. This decline followed the company's second-quarter earnings report that, although it surpassed expectations, revealed that revenue fell short of what analysts had predicted....

Continue Reading
Organon's Q4 Earnings Results: Key Highlights for Investors

Updated Category News Views 188

Understanding Organon's Q4 Earnings Results Organon (NYSE: OGN) has recently shared its earnings report, revealing critical insights that every investor should consider. The report reflects the company's financial health and performance trends over the last quarter, helping stakeholders make informed decisions. Earnings Overview In a notable announcement, Organon reported...

Continue Reading
Expanding Mental Health Services: Ana Deeter Joins Relief

Updated Category News Views 222

Expanding Mental Health Services at Relief Mental Health Relief Mental Health is excited to announce the addition of Ana Deeter, PA-C, to their team at the Northbrook clinic. Deeter, who is a board-certified physician assistant, will enhance the clinic's psychiatric services and offer SPRAVATO® (esketamine) treatment to adults seeking support. A New Specialist for...

Continue Reading
Discover BLUETTI's Cutting-Edge Energy Innovations at CES 2026

Updated Category News Views 245

Revolutionizing Energy Solutions with BLUETTI At this year's CES, BLUETTI, a leader in energy storage solutions, introduced an array of revolutionary products under the theme 'Innovate for All'. These innovations cater to the diverse demands of modern living, providing freedom and resilience for homes, vehicles, and the planet. Key Innovations from BLUETTI As BLUETTI...

Continue Reading